• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

COVID-19 危重症患者的下呼吸道微生物组。

The lower respiratory tract microbiome of critically ill patients with COVID-19.

机构信息

Operative Unit of Clinical Microbiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 9 via G. Massarenti, 40138, Bologna, Italy.

Wellmicro s.r.l, Via Piero Gobetti, 101, 40129, Bologna, Italy.

出版信息

Sci Rep. 2021 May 12;11(1):10103. doi: 10.1038/s41598-021-89516-6.

DOI:10.1038/s41598-021-89516-6
PMID:33980943
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8115177/
Abstract

COVID-19 infection may predispose to secondary bacterial infection which is associated with poor clinical outcome especially among critically ill patients. We aimed to characterize the lower respiratory tract bacterial microbiome of COVID-19 critically ill patients in comparison to COVID-19-negative patients. We performed a 16S rRNA profiling on bronchoalveolar lavage (BAL) samples collected between April and May 2020 from 24 COVID-19 critically ill subjects and 24 patients with non-COVID-19 pneumonia. Lung microbiome of critically ill patients with COVID-19 was characterized by a different bacterial diversity (PERMANOVA on weighted and unweighted UniFrac Pr(> F) = 0.001) compared to COVID-19-negative patients with pneumonia. Pseudomonas alcaligenes, Clostridium hiranonis, Acinetobacter schindleri, Sphingobacterium spp., Acinetobacter spp. and Enterobacteriaceae, characterized lung microbiome of COVID-19 critically ill patients (LDA score > 2), while COVID-19-negative patients showed a higher abundance of lung commensal bacteria (Haemophilus influenzae, Veillonella dispar, Granulicatella spp., Porphyromonas spp., and Streptococcus spp.). The incidence rate (IR) of infections during COVID-19 pandemic showed a significant increase of carbapenem-resistant Acinetobacter baumannii (CR-Ab) infection. In conclusion, SARS-CoV-2 infection and antibiotic pressure may predispose critically ill patients to bacterial superinfection due to opportunistic multidrug resistant pathogens.

摘要

COVID-19 感染可能使继发性细菌感染的易感性增加,这与不良临床结局相关,尤其是在重症患者中。我们旨在比较 COVID-19 重症患者和 COVID-19 阴性患者的下呼吸道细菌微生物组特征。我们对 2020 年 4 月至 5 月期间从 24 例 COVID-19 重症患者和 24 例非 COVID-19 肺炎患者收集的支气管肺泡灌洗液(BAL)样本进行了 16S rRNA 谱分析。与非 COVID-19 肺炎患者相比,COVID-19 重症患者的肺部微生物组具有不同的细菌多样性(加权和非加权 UniFrac Pr(>F)的 PERMANOVA = 0.001)。假单胞菌属、希氏芽孢杆菌属、产碱杆菌属、鞘氨醇单胞菌属、不动杆菌属和肠杆菌科,这些细菌特征构成了 COVID-19 重症患者的肺部微生物组(LDA 评分>2),而非 COVID-19 阴性患者则显示出更高丰度的肺部共生细菌(流感嗜血杆菌、差异韦荣球菌属、颗粒单胞菌属、卟啉单胞菌属和链球菌属)。在 COVID-19 大流行期间,感染的发生率(IR)显示出耐碳青霉烯类不动杆菌(CR-Ab)感染的显著增加。总之,SARS-CoV-2 感染和抗生素压力可能使重症患者易发生细菌合并感染,原因是机会性多重耐药病原体。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74d0/8115177/57c4774a3a31/41598_2021_89516_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74d0/8115177/ef7fa1bf70b2/41598_2021_89516_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74d0/8115177/c51ddb3ed203/41598_2021_89516_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74d0/8115177/72d303f3afb8/41598_2021_89516_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74d0/8115177/57c4774a3a31/41598_2021_89516_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74d0/8115177/ef7fa1bf70b2/41598_2021_89516_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74d0/8115177/c51ddb3ed203/41598_2021_89516_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74d0/8115177/72d303f3afb8/41598_2021_89516_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74d0/8115177/57c4774a3a31/41598_2021_89516_Fig4_HTML.jpg

相似文献

1
The lower respiratory tract microbiome of critically ill patients with COVID-19.COVID-19 危重症患者的下呼吸道微生物组。
Sci Rep. 2021 May 12;11(1):10103. doi: 10.1038/s41598-021-89516-6.
2
Signatures of COVID-19 Severity and Immune Response in the Respiratory Tract Microbiome.COVID-19 严重程度和呼吸道微生物组免疫反应特征。
mBio. 2021 Aug 31;12(4):e0177721. doi: 10.1128/mBio.01777-21. Epub 2021 Aug 17.
3
Critically ill patients with COVID-19 show lung fungal dysbiosis with reduced microbial diversity in patients colonized with Candida spp.COVID-19 重症患者表现出肺部真菌失调,定植有 Candida spp. 的患者微生物多样性减少。
Int J Infect Dis. 2022 Apr;117:233-240. doi: 10.1016/j.ijid.2022.02.011. Epub 2022 Feb 9.
4
Lung Microbiota Predict Clinical Outcomes in Critically Ill Patients.肺部微生物组预测危重症患者的临床结局。
Am J Respir Crit Care Med. 2020 Mar 1;201(5):555-563. doi: 10.1164/rccm.201907-1487OC.
5
Lung microbiome on admission in critically ill patients with acute bacterial and viral pneumonia.入住重症急性细菌性和病毒性肺炎患者的肺部微生物组。
Sci Rep. 2023 Oct 18;13(1):17724. doi: 10.1038/s41598-023-45007-4.
6
Microbial signatures in the lower airways of mechanically ventilated COVID-19 patients associated with poor clinical outcome.机械通气 COVID-19 患者下呼吸道中的微生物特征与不良临床结局相关。
Nat Microbiol. 2021 Oct;6(10):1245-1258. doi: 10.1038/s41564-021-00961-5. Epub 2021 Aug 31.
7
Divergent airway microbiomes in lung transplant recipients with or without pulmonary infection.肺移植受者中有无肺部感染的气道微生物组存在差异。
Respir Res. 2021 Apr 23;22(1):118. doi: 10.1186/s12931-021-01724-w.
8
Utility of Conventional Culture and MALDI-TOF MS for Identification of Microbial Communities in Bronchoalveolar Lavage Fluid in Comparison with the GS Junior Next Generation Sequencing System.传统培养与 MALDI-TOF MS 对支气管肺泡灌洗液微生物群落鉴定的效用比较与 GS Junior 下一代测序系统。
Ann Lab Med. 2018 Mar;38(2):110-118. doi: 10.3343/alm.2018.38.2.110.
9
The Role of Bacterial and Fungal Human Respiratory Microbiota in COVID-19 Patients.细菌和真菌在人类呼吸道微生物群在 COVID-19 患者中的作用。
Biomed Res Int. 2021 Feb 23;2021:6670798. doi: 10.1155/2021/6670798. eCollection 2021.
10
Invasive pulmonary aspergillosis in critically ill patients with severe COVID-19 pneumonia: Results from the prospective AspCOVID-19 study.重症 COVID-19 肺炎患者侵袭性肺曲霉病:前瞻性 AspCOVID-19 研究结果。
PLoS One. 2021 Mar 17;16(3):e0238825. doi: 10.1371/journal.pone.0238825. eCollection 2021.

引用本文的文献

1
A pilot study of the impact of bacterial and fungal coinfections on mildly ill COVID-19 patients.细菌和真菌合并感染对轻症COVID-19患者影响的一项初步研究。
Can J Respir Ther. 2025 Aug 12;61:182-190. doi: 10.29390/001c.142509. eCollection 2025.
2
Lung microbiota of patients with ARDS due to coronavirus disease 2019 receiving ECMO.接受体外膜肺氧合治疗的2019冠状病毒病所致急性呼吸窘迫综合征患者的肺部微生物群
Sci Rep. 2025 Jul 5;15(1):24068. doi: 10.1038/s41598-025-08664-1.
3
Lung microbiota: a new hope for treating acute respiratory distress syndrome?

本文引用的文献

1
Carbapenem-resistant bacteria in an intensive care unit during the coronavirus disease 2019 (COVID-19) pandemic: A multicenter before-and-after cross-sectional study.2019年冠状病毒病(COVID-19)大流行期间重症监护病房中的耐碳青霉烯类细菌:一项多中心前后横断面研究。
Infect Control Hosp Epidemiol. 2022 Apr;43(4):461-466. doi: 10.1017/ice.2021.144. Epub 2021 Apr 16.
2
Tocilizumab in patients with severe COVID-19: a retrospective cohort study.托珠单抗治疗重症新型冠状病毒肺炎患者:一项回顾性队列研究
Lancet Rheumatol. 2020 Aug;2(8):e474-e484. doi: 10.1016/S2665-9913(20)30173-9. Epub 2020 Jun 24.
3
Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis.
肺部微生物群:治疗急性呼吸窘迫综合征的新希望?
Front Microbiol. 2025 May 30;16:1586949. doi: 10.3389/fmicb.2025.1586949. eCollection 2025.
4
Altered microbiota of the lower respiratory tract and its association with COVID-19 severity analysed by metagenomics and metatranscriptomics.通过宏基因组学和宏转录组学分析下呼吸道微生物群的改变及其与COVID-19严重程度的关联。
Commun Biol. 2025 May 26;8(1):804. doi: 10.1038/s42003-025-08234-1.
5
tesG expression as a potential clinical biomarker for chronic Pseudomonas aeruginosa pulmonary biofilm infections.tesG表达作为慢性铜绿假单胞菌肺部生物膜感染的潜在临床生物标志物。
BMC Med. 2025 Mar 31;23(1):191. doi: 10.1186/s12916-025-04009-x.
6
Utility and Safety of Bronchoalveolar Lavage for Diagnosis and Management of Respiratory Illnesses in Immunocompromised Children.支气管肺泡灌洗在免疫功能低下儿童呼吸系统疾病诊断和管理中的应用及安全性
J Pediatric Infect Dis Soc. 2025 Mar 12;14(3). doi: 10.1093/jpids/piaf015.
7
Microbial Dynamics in COVID-19: Unraveling the Impact of Human Microbiome on Disease Susceptibility and Therapeutic Strategies.COVID-19中的微生物动态:揭示人类微生物组对疾病易感性和治疗策略的影响
Curr Microbiol. 2024 Dec 25;82(1):59. doi: 10.1007/s00284-024-04041-9.
8
Microbiome-Mucosal Immunity Nexus: Driving Forces in Respiratory Disease Progression.微生物群-黏膜免疫关系:呼吸系统疾病进展的驱动因素
J Microbiol. 2024 Sep;62(9):709-725. doi: 10.1007/s12275-024-00167-4. Epub 2024 Sep 6.
9
Microbiota and Immunity during Respiratory Infections: Lung and Gut Affair.呼吸道感染期间的微生物组和免疫:肺部和肠道的关联。
Int J Mol Sci. 2024 Apr 5;25(7):4051. doi: 10.3390/ijms25074051.
10
Signatures of disease outcome severity in the intestinal fungal and bacterial microbiome of COVID-19 patients.COVID-19 患者肠道真菌和细菌微生物组中疾病结局严重程度的特征。
Front Cell Infect Microbiol. 2024 Mar 6;14:1352202. doi: 10.3389/fcimb.2024.1352202. eCollection 2024.
COVID-19 患者的细菌合并感染和继发感染:一项实时快速综述和荟萃分析。
Clin Microbiol Infect. 2020 Dec;26(12):1622-1629. doi: 10.1016/j.cmi.2020.07.016. Epub 2020 Jul 22.
4
The lung tissue microbiota features of 20 deceased patients with COVID-19.20例COVID-19死亡患者的肺组织微生物群特征
J Infect. 2020 Sep;81(3):e64-e67. doi: 10.1016/j.jinf.2020.06.047. Epub 2020 Jun 21.
5
Co-infections in people with COVID-19: a systematic review and meta-analysis.COVID-19 患者合并感染:系统评价和荟萃分析。
J Infect. 2020 Aug;81(2):266-275. doi: 10.1016/j.jinf.2020.05.046. Epub 2020 May 27.
6
Co-infection with respiratory pathogens among COVID-2019 cases.COVID-19 病例中呼吸道病原体的合并感染。
Virus Res. 2020 Aug;285:198005. doi: 10.1016/j.virusres.2020.198005. Epub 2020 May 11.
7
Coronavirus Disease 2019, Superinfections, and Antimicrobial Development: What Can We Expect?新型冠状病毒肺炎、合并感染与抗菌药物研发:我们有何期待?
Clin Infect Dis. 2020 Dec 17;71(10):2736-2743. doi: 10.1093/cid/ciaa524.
8
Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China.中国武汉 221 例 COVID-19 患者的临床特征和短期预后。
J Clin Virol. 2020 Jun;127:104364. doi: 10.1016/j.jcv.2020.104364. Epub 2020 Apr 9.
9
Genomic Diversity of Severe Acute Respiratory Syndrome-Coronavirus 2 in Patients With Coronavirus Disease 2019.2019 年冠状病毒病患者中严重急性呼吸综合征冠状病毒 2 的基因组多样性。
Clin Infect Dis. 2020 Jul 28;71(15):713-720. doi: 10.1093/cid/ciaa203.
10
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.